Covid-19 Pandemic: India's Zydus Cadila Signs Pact with Gilead Sciences to Make Antiviral Drug Remdesivir
Covid-19 Pandemic: India's Zydus Cadila Signs Pact with Gilead Sciences to Make Antiviral Drug Remdesivir
Antiviral drug remdesivir is the first treatment to show improvement in COVID-19 trials.

Indian drugmaker Zydus Cadila said on Friday it signed a non-exclusive agreement with Gilead Sciences Inc to manufacture and market antiviral drug remdesivir, the first treatment to show improvement in COVID-19 trials.

What's your reaction?

Comments

https://umorina.info/assets/images/user-avatar-s.jpg

0 comment

Write the first comment for this!